Physician profile
Tamara Richards
NPI 1447461736
$1,745.96
in general payments reported to CMS, 2019-2025
32 companies · $463 in 2025
The $463 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $120 · 2021: $111 · 2022: $207 · 2023: $298 · 2024: $267 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Consulting Fee: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.52 |
| Consulting Fee | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $223.83 | 2019-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Abbvie INC. | $179.30 | 2019-2022 | |
| Myriad Women'S Health, INC. | $145.59 | 2023 | Myrisk |
| Meditrina | $108.60 | 2022-2024 | |
| Organon LLC | $96.04 | 2022-2025 | Nexplanon, Nuvaring |
| Sumitomo Pharma America, INC. | $90.15 | 2025 | Myfembree |
| Astellas Pharma US INC | $80.63 | 2019-2024 | Veozah |
| Therapeuticsmd, INC. | $78.97 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $70.43 | 2019-2025 | Exparel |
| Shield Therapeutics INC | $62.30 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $62.10 | 2025 | |
| Coopersurgical, INC. | $61.13 | 2019-2024 | Summit Doppler, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $39.97 | 2019-2020 | |
| Exact Sciences Corporation | $38.20 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $35.32 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $34.84 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $32.82 | 2025 | |
| Axonics, INC. | $32.31 | 2023 | Axonics |
| Biogen, INC. | $28.64 | 2025 | Zurzuvae |
| Dexcom, INC. | $28.02 | 2025 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $26.21 | 2022 | |
| Conmed Corporation | $25.62 | 2022 | |
| Millicent US INC | $22.41 | 2024 | Intrarosa |
| Pfizer INC. | $19.47 | 2024 | |
| Scynexis, INC. | $19.36 | 2022 | |
| Myovant Sciences INC. | $18.67 | 2022 | |
| Roche Diagnostics Corporation | $17.26 | 2019 | |
| Lilly USA, LLC | $15.51 | 2025 | Zepbound |
| Guard Medical INC. | $13.75 | 2025 | Npseal |
| Covidien LP | $13.56 | 2020 | |
| Minerva Surgical, INC | $12.54 | 2020 | |
| Allergan, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.